Latest Hotspot

Monopar Gets Approval to Start Phase 1 Trial of New Radiopharmaceutical for Advanced Cancers

26 August 2024
3 min read

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage company specializing in radiopharmaceuticals for cancer treatment, revealed that it has obtained Human Research Ethics Committee (HREC) approval in Australia to initiate a Phase 1 clinical trial for its innovative radiopharmaceutical MNPR-101-Lu.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

MNPR-101-Lu fuses the therapeutic radioisotope lutetium-177 (Lu-177) with Monopar’s proprietary humanized monoclonal antibody  MNPR-101, which specifically targets the urokinase plasminogen activator receptor (uPAR). The Phase 1 clinical trial for MNPR-101-Lu aims to enroll patients with advanced solid tumors and will act as a therapeutic extension to the ongoing MNPR-101-Zr imaging and dosimetry trial.

Preclinical studies of MNPR-101-Lu show promising results. In a 90-day study evaluating efficacy in a human pancreatic cancer xenograft mouse model, a single injection of MNPR-101-Lu induced sustained antitumor activities, completely eliminating tumors for the study's entire duration.

Additional insights into the therapeutic efficacy were provided by imaging data from a human pancreatic cancer xenograft mouse model presented in March (see link and Figure 2 below). The imaging results indicate high specificity and sustained uptake of MNPR-101-Lu within the tumor as compared to normal tissues.

“We are thrilled with the HREC clearance and optimistic about the potential of MNPR-101-Lu to offer substantial clinical benefits for patients with uPAR-positive tumors,” commented Chandler Robinson, MD, Monopar’s Chief Executive Officer. “Several highly aggressive and lethal cancers, such as triple-negative breast cancer and pancreatic cancer, express uPAR. We are eager to initiate the trial as swiftly as possible.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of August 26, 2024, there are 18 investigational drugs for the uPAR target, including 37 indications, 16 R&D institutions involved, with related clinical trials reaching 15, and as many as 14345 patents.

MNPR-101 is a monoclonal antibody drug developed by Monopar Therapeutics, Inc., with its highest phase being pending. The drug targets uPAR and is intended for use in the therapeutic areas of neoplasms. Monoclonal antibodies are a type of biopharmaceutical drug that are designed to target specific proteins in the body. In the case of MNPR-101, the target is uPAR, which is a receptor that is often overexpressed in cancer cells. By targeting uPAR, MNPR-101 aims to inhibit the growth and spread of neoplastic cells, potentially offering a new treatment option for cancer patients.

图形用户界面, 文本, 应用程序

描述已自动生成

Global New Drug Research and Development Progress Weekly Report (8.19-8.25)
Drug Highlight
15 min read
Global New Drug Research and Development Progress Weekly Report (8.19-8.25)
26 August 2024
8.19-8.25 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Read →
D&D Pharmatech Initiates Phase 2 Trial of DD01 for Obesity-Related MASLD/MASH Treatment
Latest Hotspot
4 min read
D&D Pharmatech Initiates Phase 2 Trial of DD01 for Obesity-Related MASLD/MASH Treatment
23 August 2024
D&D Pharmatech begins Phase 2 trial for DD01, a long-lasting dual GLP-1/Glucagon receptor agonist, to assess its safety and efficacy in overweight/obese individuals with MASLD/MASH.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 23
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 23
23 August 2024
Aug 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
NPMA Accepts Second NDA for Kelun-Biotech’s SKB264 in EGFR-Mutant NSCLC
Latest Hotspot
4 min read
NPMA Accepts Second NDA for Kelun-Biotech’s SKB264 in EGFR-Mutant NSCLC
23 August 2024
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) has had its second NDA accepted by NPMA for locally advanced or metastatic EGFR-mutant NSCLC.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.